BNGO logo

Bionano Genomics (BNGO) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

21 August 2018

Indexes:

Not included

Description:

Bionano Genomics (BNGO) is a biotechnology company that develops tools for genome analysis. Their main product, the Saphyr system, helps researchers identify genetic variations and structural changes in DNA. This technology supports advancements in personalized medicine and cancer research, improving understanding of genetic diseases.

Events Calendar

Earnings

Next earnings date:

Mar 05, 2025

Recent quarterly earnings:

Nov 05, 2024

Recent annual earnings:

Mar 05, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Aug 07, 2023

Analyst ratings

Recent major analysts updates

15 Nov '24 Ladenburg Thalmann
Neutral
16 May '24 BTIG
Buy
07 Mar '24 Scotiabank
Sector Outperform
13 Nov '23 Maxim Group
Hold
10 Aug '23 BTIG
Buy
09 June '23 BTIG
Buy
25 May '23 EF Hutton
Buy
18 May '23 BTIG
Buy
24 Apr '23 BTIG
Buy
10 Mar '23 BTIG
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
BNGO
globenewswire.com31 December 2024

SAN DIEGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a settlement agreement and amendment to its outstanding senior secured convertible debentures due May 26, 2024 (the “Amendment”). Importantly the Amendment defers the Company's December 2024 amortization payment and reduces the payments due in January 2025 through July 2025 from $1,000,000 per month to $500,000 per month.

Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis
BNGO
globenewswire.com23 December 2024

SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Modern Pathology by a group of researchers at the Johns Hopkins University School of Medicine, showing that optical genome mapping (OGM) can outperform traditional techniques in analysis of bone and soft tissue tumors. Several prior publications have shown the utility of OGM compared to traditional cytogenetics in studies of hematologic malignancies, however, data on the application of OGM in solid tumors has been relatively sparse. This study provides compelling support for extending the utility of OGM in cancer beyond hematologic malignancies to solid tumors.

Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
BNGO
seekingalpha.com13 November 2024

Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Destiny Hance - Ladenburg Thalmann Mark Massaro - BTIG Operator Good day, and welcome to the Bionano Third Quarter 2024 Earnings Conference Call. Today's conference is being recorded.

Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
BNGO
globenewswire.com31 October 2024

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it adjourned its reconvened Special Meeting of Stockholders originally held on October 2, 2024 and subsequently adjourned to October 30, 2024 (the “Special Meeting”) because a quorum was not present at the time of the reconvened meeting. Based on preliminary reports as of October 30, 2024, approximately 30.7% of total shares outstanding as of the record date have submitted their votes, whereas 33.3% of total shares outstanding as of the record date are necessary to satisfy the quorum requirements for a meeting.

Bionano Announces Preliminary 3Q 2024 Revenues and Cash
Bionano Announces Preliminary 3Q 2024 Revenues and Cash
Bionano Announces Preliminary 3Q 2024 Revenues and Cash
BNGO
globenewswire.com10 October 2024

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced select preliminary results for the quarter ended September 30, 2024. The Company now expects revenue for the third quarter of 2024 to be between $6.5 and $6.8 million, down from prior guidance of between $7.9 and $8.9 million.

Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript)
Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript)
Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript)
BNGO
seekingalpha.com13 August 2024

Bionano Genomics, Inc. (NASDAQ:BNGO ) Canaccord Genuity 44th Annual Growth Results Conference August 13, 2024 3:30 PM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Kyle Mikson Hi. Welcome to the Canaccord Genuity Global Growth Conference.

Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
BNGO
zacks.com13 August 2024

Bionano Genomics (BNGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
BNGO
globenewswire.com07 August 2024

Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023 Sold 6,165 nanochannel array flowcells in Q2 2024, which represents a 13% decrease from the number of flowcells sold in Q2 2023 The editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies Conference call today, August 7th, 2024 at 4:30 PM ET SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2024. “We saw positive growth in the OGM installed base this quarter, along with key advancements to our VIA software and the achievement of a significant milestone with the establishment of a Category I CPT code for OGM, which we believe will raise the awareness and utility of OGM,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference
Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference
Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference
BNGO
globenewswire.com31 July 2024

SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024.

3 Sorry Healthcare Stocks to Sell in May While You Still Can
3 Sorry Healthcare Stocks to Sell in May While You Still Can
3 Sorry Healthcare Stocks to Sell in May While You Still Can
BNGO
investorplace.com28 May 2024

Healthcare stocks often hold significant potential due to the constant demand for medical advancements. However, not all companies in this sector are poised for growth.

FAQ

  • What is the primary business of Bionano Genomics?
  • What is the ticker symbol for Bionano Genomics?
  • Does Bionano Genomics pay dividends?
  • What sector is Bionano Genomics in?
  • What industry is Bionano Genomics in?
  • What country is Bionano Genomics based in?
  • When did Bionano Genomics go public?
  • Is Bionano Genomics in the S&P 500?
  • Is Bionano Genomics in the NASDAQ 100?
  • Is Bionano Genomics in the Dow Jones?
  • When was Bionano Genomics's last earnings report?
  • When does Bionano Genomics report earnings?
  • Should I buy Bionano Genomics stock now?

What is the primary business of Bionano Genomics?

Bionano Genomics (BNGO) is a biotechnology company that develops tools for genome analysis. Their main product, the Saphyr system, helps researchers identify genetic variations and structural changes in DNA. This technology supports advancements in personalized medicine and cancer research, improving understanding of genetic diseases.

What is the ticker symbol for Bionano Genomics?

The ticker symbol for Bionano Genomics is NASDAQ:BNGO

Does Bionano Genomics pay dividends?

No, Bionano Genomics does not pay dividends

What sector is Bionano Genomics in?

Bionano Genomics is in the Healthcare sector

What industry is Bionano Genomics in?

Bionano Genomics is in the Medical Instruments & Supplies industry

What country is Bionano Genomics based in?

Bionano Genomics is headquartered in United States

When did Bionano Genomics go public?

Bionano Genomics's initial public offering (IPO) was on 21 August 2018

Is Bionano Genomics in the S&P 500?

No, Bionano Genomics is not included in the S&P 500 index

Is Bionano Genomics in the NASDAQ 100?

No, Bionano Genomics is not included in the NASDAQ 100 index

Is Bionano Genomics in the Dow Jones?

No, Bionano Genomics is not included in the Dow Jones index

When was Bionano Genomics's last earnings report?

Bionano Genomics's most recent earnings report was on 5 November 2024

When does Bionano Genomics report earnings?

The next expected earnings date for Bionano Genomics is 5 March 2025

Should I buy Bionano Genomics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions